Attached files
file | filename |
---|---|
8-K - FORM 8-K - ChromaDex Corp. | cdxc8k_mar272017.htm |
Exhibit 99.1
ChromaDex Appoints Steven D. Rubin, J.D., to its Board of
Directors
IRVINE, Calif., March 28, 2017 –
ChromaDex Corp. (NASDAQ: CDXC), an
innovator of proprietary health, wellness and nutritional
ingredients that creates science-based solutions for dietary
supplement, food and beverage, skin care, sports nutrition, and
pharmaceutical products, announced today that Steven D. Rubin, J.D.
has joined the Company’s board of directors.
Mr.
Rubin, age 56, has served as OPKO Health, Inc.’s (NASDAQ:
OPK) Executive Vice President – Administration since May 2007
and as a director of since February 2007. Mr. Rubin is a member of
The Frost Group, LLC, a private investment firm. He has extensive
experience as a practicing lawyer, and as general counsel and board
member to multiple public companies.
Mr.
Rubin currently serves on the board of directors for the following
companies: VBI Vaccines Inc., a commercial-stage biopharmaceutical
company developing a next generation of vaccines; Cognit, Inc., a
data and analytics company providing cloud-based mission-critical
information and performance marketing solutions; Kidville, Inc., an
operator of large, upscale facilities, catering to newborns through
five-year-old children and their families and offers a wide range
of developmental classes for newborns to five-year-olds;
Non-Invasive Monitoring Systems, Inc., a medical device company;
BioCardia, Inc., , a clinical-stage regenerative medicine company
developing novel therapeutics for cardiovascular diseases;
Cocrystal Pharma, Inc., a biotechnology company developing new
treatments for viral diseases; Sevion Therapeutics, Inc., a
clinical stage company which discovers and develops next-generation
biologics for the treatment of cancer and immunological diseases;
Castle Brands, Inc.), a developer and marketer of premium brand
spirits; and, Neovasc, Inc., a company developing and marketing
medical specialty vascular devices.
Mr.
Rubin previously served as the Senior Vice President, General
Counsel and Secretary of IVAX from August 2001 until September
2006. Mr. Rubin previously served as a director of the following
companies: Dreams, Inc. (NYSE MKT: DRJ), a vertically integrated
sports licensing and products company; Safestitch Medical, Inc.
prior to its merger with TransEnterix, Inc.; and, PROLOR Biotech,
Inc., prior to its acquisition by the Company in August
2013.
About ChromaDex:
ChromaDex
leverages its complementary business units to discover, acquire,
develop and commercialize patented and proprietary ingredient
technologies that address the dietary supplement, food, beverage,
skin care and pharmaceutical markets. In addition to our ingredient
technologies unit, we also have business units focused on natural
product fine chemicals (known as "phytochemicals"), chemistry and
analytical testing services, and product regulatory and safety
consulting. As a result of our relationships with leading
universities and research institutions, we are able to discover and
license early stage, IP-backed ingredient technologies. We then
utilize our in-house chemistry, regulatory and safety consulting
business units to develop commercially viable ingredients. Our
ingredient portfolio is backed with clinical and scientific
research, as well as extensive IP protection. Our portfolio of
patented ingredient technologies includes
NIAGEN®
nicotinamide riboside; pTeroPure®
pterostilbene; PURENERGY®,
a caffeine-pTeroPure® co-crystal;
IMMULINA™,
a spirulina extract; and AnthOrigin™,
anthocyanins derived from a domestically-produced, water-extracted
purple corn. To learn more about ChromaDex, please visit
www.ChromaDex.com.
Forward-Looking Statements:
This
release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities and Exchange Act of 1934, as
amended, including statements related to the composition and
experience of ChromaDex’s board of directors. Statements that
are not a description of historical facts constitute
forward-looking statements and may often, but not always, be
identified by the use of such words as "expects", "anticipates",
"intends", "estimates", "plans", "potential", "possible",
"probable", "believes", "seeks", "may", "will", "should", "could"
or the negative of such terms or other similar expressions. More
detailed information about ChromaDex and the risk factors that may
affect the realization of forward-looking statements is set forth
in ChromaDex's Annual Report on Form 10-K for the fiscal year ended
December 31, 2016, ChromaDex's Quarterly Reports on Form 10-Q and
other filings submitted by ChromaDex to the SEC, copies of which
may be obtained from the SEC's website at www.sec.gov.
Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof,
and actual results may differ materially from those suggested by
these forward-looking statements. All forward-looking statements
are qualified in their entirety by this cautionary statement and
ChromaDex undertakes no obligation to revise or update this release
to reflect events or circumstances after the date
hereof.
ChromaDex Investor Relations Contact:
Andrew
Johnson, Director of Investor Relations
949-419-0288
andrewj@chromadex.com
ChromaDex Public Relations Contact:
Breah
Ostendorf, Director of Marketing
949-537-4103
breaho@chromadex.com
END
###